Activity

ACTION ITEMS ✨ Email Maria re immunosuppressants quote details (custom L3 w/ lower cyclosporine conc, price L1+L2 customs) Andrew Hartmann Contact purchasing team re metals testing orders, identify end user Andrew Hartmann Send UTAK stability data for alpha-nol control in Oct (if available) Cid, Maria MEETING SUMMARY ✨ Chronological Template Customize • Change Template Dedicated account representative @ 0:00 Andrew Hartmann has been assigned as the dedicated account representative for New York Presbyterian. He will be the single point of contact for any needs or questions. Changes to UTAK's production process @ 0:48 UTAK is making changes to their production process for stock products, including smaller batch sizes and more frequent manufacturing to provide longer expiration dates. This may impact how New York Presbyterian orders and manages their inventory. Custom controls for immunosuppressants @ 1:28 New York Presbyterian is increasing their use of immunosuppressant controls, particularly for cyclosporine. UTAK will provide a quote for a custom level 3 control with a lower cyclosporine concentration, as well as custom level 1 and 2 controls. Upcoming assay changes at New York Presbyterian @ 5:29 New York Presbyterian plans to transfer their clozapine and lamotrigine assays from HPLC to LC-MS, potentially adding additional anti-psychotic and anti-epileptic compounds. They will reach out to UTAK once they have finalized the details. Feedback and areas for improvement @ 10:14 New York Presbyterian rates UTAK an 8 out of 10, citing the long lead times and high cost of the alphanol control as areas for improvement. They appreciate UTAK's responsiveness in replacing defective products and the ability to have open conversations about custom controls. Ongoing partnership and future collaboration @ 14:13 Both parties express interest in continuing their strong partnership, with New York Presbyterian open to providing feedback and participating in UTAK's product development efforts in the future.